ReviewMediterranean journal of hematology and infectious diseases2019
Pregnancy in Thalassemia.
Review in Mediterranean journal of hematology and infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Addressing Obstetric and Gynecologic Needs in Thalassemia.O&G open · 2026Article
- Pregnancy and childbirth in women with thalassemia: past and present.Haematologica · 2026Article
- Adapting haematology practices for effective management of blood disorders in pregnancy in a limited resource setting.Annals of hematology · 2025Review
- Cellular and molecular targets in β-Thalassemia: advances in iron Regulation, Erythropoiesis, and Gene-Based therapies.Functional & integrative genomics · 2025Review
- In vitro fertilization as an option for couples with genetic disorders.Clinical and experimental reproductive medicine · 2025Article
- Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice.Journal of clinical medicine · 2025Article
- Melanin Nanoparticles as a Safe and Effective Iron Chelation Therapy: An ex vivo Assessment of Human Placental Transfer in Pregnant Beta-Thalassemia.International journal of nanomedicine · 2025Article
- Article
- Investigation of the Influence of Deletional and Non-Deletional Hemoglobin H Disease on Pregnancy Outcomes.International journal of women's health · 2025Article
- Sex and Gender Differences in Iron Chelation.Biomedicines · 2024Review
- Iron overload in anaemia with underlying haemoglobin constant spring in an antenatal mother in primary care.BMJ case reports · 2024Article
- Experiences, Knowledge Gaps and Information Needs of Women in Australia with Transfusion Dependent Thalassaemia in Regard to Fertility and Pregnancy.Maternal and child health journal · 2023Article
- Knowledge Gaps and Current Evidence Regarding Breastfeeding Issues in Mothers with Chronic Diseases.Nutrients · 2023Review
- New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.Diagnostics (Basel, Switzerland) · 2022Review
- Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies.Journal of clinical medicine · 2022Article
- Current status of beta-thalassemia and its treatment strategies.Molecular genetics & genomic medicine · 2021Review
- Recommendations for Pregnancy in Rare Inherited Anemias.HemaSphere · 2020Review
- Pregnancy in Thalassemia and Sickle Cell Disease: The Experience of an Italian Thalassemia Center.Frontiers in molecular biosciences · 2020Article
- The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.Mediterranean journal of hematology and infectious diseases · 2020Review
- Fertility in Patients with Thalassemia and Outcome of Pregnancies: A Turkish ExperienceTurkish journal of haematology : official journal of Turkish Society of Haematology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic advances, including the availability of oral iron chelators and new non-invasive methods for early detection and treatment of iron overload, have significantly improved the life expectancy and quality of thalassemia patients, with a consequent increase in their reproductive potential and desire to have children. Hundreds of pregnancies have been reported so far, highlighting that women carefully managed in the preconception phase usually carry out a successful gestation and labor, both in case of spontaneous conception and assisted reproductive techniques. A multidisciplinary team including a cardiologist, an endocrinologist, and a gynecologist, under the supervision of an expert in beta-thalassemia, should be involved. During pregnancy, a close follow-up of maternal disorders and of the baby's status is recommended. Hemoglobin should be maintained over 10 g/dL to allow normal fetal growth. Chelators are not recommended; nevertheless, it may be reasonable to consider restarting chelation therapy with desferrioxamine towards the end of the second trimester when the potential benefits outweigh the potential fetal risk. Women with non-transfusion-dependent thalassemia who have never previously been transfused or who have received only minimal transfusion therapy are at risk of severe alloimmune anemia if blood transfusions are required during pregnancy. Since pregnancy increases the risk of thrombosis three-fold to four-fold and thalassemia is also a hypercoagulable state, the recommendation is to keep women who are at higher risk -such as those who are not regularly transfused and those splenectomised- on prophylaxis during pregnancy and the postpartum period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.